<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p173" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_173{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_173{left:306px;bottom:30px;}
#t3_173{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_173{left:346px;bottom:30px;}
#t5_173{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_173{left:517px;bottom:30px;}
#t7_173{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_173{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_173{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_173{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_173{left:35px;bottom:777px;letter-spacing:0.2px;}
#tc_173{left:35px;bottom:748px;letter-spacing:0.05px;word-spacing:0.13px;}
#td_173{left:35px;bottom:724px;letter-spacing:0.11px;word-spacing:0.08px;}
#te_173{left:35px;bottom:701px;letter-spacing:0.11px;word-spacing:0.08px;}
#tf_173{left:35px;bottom:678px;letter-spacing:0.11px;}
#tg_173{left:94px;bottom:686px;}
#th_173{left:138px;bottom:678px;letter-spacing:0.1px;word-spacing:-1.15px;}
#ti_173{left:35px;bottom:655px;letter-spacing:0.11px;word-spacing:-0.98px;}
#tj_173{left:35px;bottom:633px;letter-spacing:0.07px;word-spacing:-1.01px;}
#tk_173{left:35px;bottom:610px;letter-spacing:0.19px;word-spacing:-1.24px;}
#tl_173{left:169px;bottom:617px;letter-spacing:0.61px;}
#tm_173{left:183px;bottom:610px;letter-spacing:0.07px;word-spacing:0.12px;}
#tn_173{left:516px;bottom:617px;letter-spacing:-0.01px;}
#to_173{left:539px;bottom:610px;letter-spacing:0.18px;}
#tp_173{left:35px;bottom:586px;letter-spacing:0.08px;word-spacing:0.11px;}
#tq_173{left:35px;bottom:563px;letter-spacing:0.14px;word-spacing:0.05px;}
#tr_173{left:35px;bottom:540px;letter-spacing:0.05px;word-spacing:0.14px;}
#ts_173{left:35px;bottom:517px;letter-spacing:0.01px;word-spacing:0.17px;}
#tt_173{left:35px;bottom:493px;letter-spacing:0.12px;word-spacing:0.07px;}
#tu_173{left:251px;bottom:501px;}
#tv_173{left:35px;bottom:453px;letter-spacing:0.03px;word-spacing:0.15px;}
#tw_173{left:35px;bottom:430px;letter-spacing:0.11px;word-spacing:-1.16px;}
#tx_173{left:578px;bottom:437px;}
#ty_173{left:35px;bottom:407px;letter-spacing:0.03px;word-spacing:-1.07px;}
#tz_173{left:35px;bottom:383px;letter-spacing:0.06px;word-spacing:0.12px;}
#t10_173{left:35px;bottom:360px;letter-spacing:0.12px;word-spacing:-0.24px;}
#t11_173{left:35px;bottom:337px;letter-spacing:0.03px;word-spacing:0.15px;}
#t12_173{left:500px;bottom:345px;letter-spacing:-0.01px;}
#t13_173{left:523px;bottom:337px;letter-spacing:-0.27px;}
#t14_173{left:35px;bottom:314px;letter-spacing:0.08px;word-spacing:0.26px;}
#t15_173{left:35px;bottom:291px;letter-spacing:0.02px;word-spacing:-0.82px;}
#t16_173{left:35px;bottom:267px;letter-spacing:0.16px;word-spacing:-1.21px;}
#t17_173{left:213px;bottom:275px;letter-spacing:-0.15px;}
#t18_173{left:291px;bottom:267px;letter-spacing:0.03px;word-spacing:-0.67px;}
#t19_173{left:35px;bottom:244px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1a_173{left:35px;bottom:221px;letter-spacing:0.06px;word-spacing:-0.33px;}
#t1b_173{left:35px;bottom:198px;letter-spacing:0.12px;word-spacing:-0.75px;}
#t1c_173{left:35px;bottom:174px;letter-spacing:0.09px;word-spacing:-0.05px;}
#t1d_173{left:35px;bottom:151px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1e_173{left:35px;bottom:128px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1f_173{left:332px;bottom:136px;letter-spacing:0.12px;}
#t1g_173{left:35px;bottom:89px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1h_173{left:35px;bottom:66px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t1i_173{left:187px;bottom:66px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1j_173{left:618px;bottom:777px;letter-spacing:0.19px;}
#t1k_173{left:618px;bottom:754px;letter-spacing:0.14px;}
#t1l_173{left:700px;bottom:761px;letter-spacing:-0.05px;}
#t1m_173{left:786px;bottom:754px;letter-spacing:0.05px;word-spacing:-0.02px;}
#t1n_173{left:618px;bottom:731px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1o_173{left:618px;bottom:707px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1p_173{left:618px;bottom:684px;word-spacing:0.18px;}
#t1q_173{left:618px;bottom:661px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1r_173{left:618px;bottom:638px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1s_173{left:618px;bottom:614px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1t_173{left:618px;bottom:575px;letter-spacing:0.02px;word-spacing:-0.79px;}
#t1u_173{left:618px;bottom:552px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1v_173{left:618px;bottom:529px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1w_173{left:618px;bottom:506px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1x_173{left:618px;bottom:482px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1y_173{left:779px;bottom:490px;letter-spacing:-0.01px;}
#t1z_173{left:802px;bottom:482px;letter-spacing:0.15px;word-spacing:0.03px;}
#t20_173{left:618px;bottom:459px;letter-spacing:-0.04px;word-spacing:-0.32px;}
#t21_173{left:618px;bottom:436px;letter-spacing:0.11px;word-spacing:0.08px;}
#t22_173{left:618px;bottom:413px;letter-spacing:0.11px;word-spacing:0.07px;}
#t23_173{left:618px;bottom:390px;letter-spacing:0.11px;word-spacing:-0.15px;}
#t24_173{left:618px;bottom:366px;letter-spacing:0.09px;word-spacing:-1.12px;}
#t25_173{left:618px;bottom:343px;letter-spacing:0.08px;word-spacing:0.1px;}
#t26_173{left:809px;bottom:351px;letter-spacing:0.1px;}
#t27_173{left:854px;bottom:343px;letter-spacing:0.17px;word-spacing:0.02px;}
#t28_173{left:618px;bottom:320px;letter-spacing:0.03px;word-spacing:0.16px;}
#t29_173{left:618px;bottom:297px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2a_173{left:618px;bottom:273px;letter-spacing:0.11px;word-spacing:0.21px;}
#t2b_173{left:618px;bottom:250px;letter-spacing:0.13px;word-spacing:0.07px;}
#t2c_173{left:618px;bottom:227px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2d_173{left:618px;bottom:204px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2e_173{left:1095px;bottom:211px;letter-spacing:-0.01px;}
#t2f_173{left:1118px;bottom:204px;letter-spacing:0.45px;}
#t2g_173{left:618px;bottom:181px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2h_173{left:618px;bottom:157px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2i_173{left:618px;bottom:134px;letter-spacing:0.07px;word-spacing:-1.11px;}
#t2j_173{left:804px;bottom:142px;letter-spacing:-0.01px;}
#t2k_173{left:827px;bottom:134px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2l_173{left:618px;bottom:111px;letter-spacing:0.11px;word-spacing:-0.42px;}
#t2m_173{left:618px;bottom:88px;letter-spacing:0.17px;word-spacing:0.01px;}
#t2n_173{left:618px;bottom:64px;letter-spacing:0.11px;word-spacing:-0.74px;}
#t2o_173{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_173{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_173{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_173{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_173{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_173{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_173{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_173{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_173{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts173" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg173Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg173" style="-webkit-user-select: none;"><object width="1210" height="935" data="173/173.svg" type="image/svg+xml" id="pdf173" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_173" class="t s0_173">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_173" class="t s1_173">© </span>
<span id="t3_173" class="t s0_173">(NCCN </span>
<span id="t4_173" class="t s1_173">© </span>
<span id="t5_173" class="t s0_173">), All rights reserved. NCCN Guidelines </span>
<span id="t6_173" class="t s1_173">® </span>
<span id="t7_173" class="t s0_173">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_173" class="t s2_173">NCCN Guidelines Version 4.2024 </span>
<span id="t9_173" class="t s2_173">Head and Neck Cancers </span>
<span id="ta_173" class="t s3_173">MS-32 </span>
<span id="tb_173" class="t s3_173">Treatment </span>
<span id="tc_173" class="t s4_173">Expert consensus is that HPV status should be used as a stratification </span>
<span id="td_173" class="t s4_173">factor or should be addressed in separate trials (HPV-related vs. - </span>
<span id="te_173" class="t s4_173">unrelated disease) for which patients with oropharyngeal cancer are </span>
<span id="tf_173" class="t s4_173">eligible. </span>
<span id="tg_173" class="t s5_173">429-431 </span>
<span id="th_173" class="t s4_173">With some exceptions, which are noted in this section below, </span>
<span id="ti_173" class="t s4_173">the treatment algorithms for p16-negative and p16-positive oropharyngeal </span>
<span id="tj_173" class="t s4_173">cancer are identical. There is currently no evidence that the staging criteria </span>
<span id="tk_173" class="t s4_173">published in the 8 </span>
<span id="tl_173" class="t s5_173">th </span>
<span id="tm_173" class="t s4_173">edition of the AJCC Cancer Staging Manual </span>
<span id="tn_173" class="t s5_173">391 </span>
<span id="to_173" class="t s4_173">should </span>
<span id="tp_173" class="t s4_173">drive clinical decision-making, as it is currently unknown how to </span>
<span id="tq_173" class="t s4_173">therapeutically address the vast biological differences between the two </span>
<span id="tr_173" class="t s4_173">distinct cancers. Panel members urge that patients with HPV-positive </span>
<span id="ts_173" class="t s4_173">cancers be enrolled in clinical trials evaluating biological and </span>
<span id="tt_173" class="t s4_173">treatment-related questions. </span>
<span id="tu_173" class="t s5_173">432-434 </span>
<span id="tv_173" class="t s4_173">Some clinicians have suggested that less-intense treatment may be </span>
<span id="tw_173" class="t s4_173">adequate for HPV-positive oropharyngeal cancers (ie, deintensification). </span>
<span id="tx_173" class="t s5_173">48 </span>
<span id="ty_173" class="t s4_173">While not considered deintensification, other RT-based strategies that may </span>
<span id="tz_173" class="t s4_173">be used to potentially minimize harm in patients with p16-positive </span>
<span id="t10_173" class="t s4_173">oropharyngeal cancer include use of image-guided RT and consideration </span>
<span id="t11_173" class="t s4_173">of unilateral neck irradiation in disease that is well-lateralized. </span>
<span id="t12_173" class="t s5_173">435 </span>
<span id="t13_173" class="t s4_173">Available </span>
<span id="t14_173" class="t s4_173">data supporting these assertions are limited by retrospective analyses, </span>
<span id="t15_173" class="t s4_173">single-institution phase 3 trials, variability in HPV testing method used, and </span>
<span id="t16_173" class="t s4_173">short follow-up periods. </span>
<span id="t17_173" class="t s5_173">48,433,436,437 </span>
<span id="t18_173" class="t s4_173">Deintensification treatment protocols for </span>
<span id="t19_173" class="t s4_173">HPV-positive locally advanced oropharyngeal cancer are being </span>
<span id="t1a_173" class="t s4_173">investigated in ongoing clinical trials. Strategies under active investigation </span>
<span id="t1b_173" class="t s4_173">include reducing or using biomarker or response-stratified RT dose, using </span>
<span id="t1c_173" class="t s4_173">RT alone versus chemoradiation, using less invasive surgical procedures </span>
<span id="t1d_173" class="t s4_173">such as transoral laser microsurgery or TORS, using sequential systemic </span>
<span id="t1e_173" class="t s4_173">therapy/RT, and using immunotherapy. </span>
<span id="t1f_173" class="t s5_173">433,435,438 </span>
<span id="t1g_173" class="t s4_173">Early-stage (T1–2, N0–1 for p16-negative disease; T1–2, N0 or single </span>
<span id="t1h_173" class="t s6_173">node ≤3 cm for p16</span><span id="t1i_173" class="t s4_173">-positive disease) oropharyngeal cancers may be </span>
<span id="t1j_173" class="t s4_173">treated with definitive RT or resection of the primary with neck </span>
<span id="t1k_173" class="t s4_173">dissection. </span>
<span id="t1l_173" class="t s5_173">112,115,439,440 </span>
<span id="t1m_173" class="t s4_173">Tumors at or approaching the midline (ie, tumors in </span>
<span id="t1n_173" class="t s4_173">the base of the tongue, posterior pharyngeal wall, soft palate, and tonsil </span>
<span id="t1o_173" class="t s4_173">invading the tongue base) are at risk of contralateral metastasis and </span>
<span id="t1p_173" class="t s4_173">warrant bilateral treatment. A staged contralateral neck dissection can be </span>
<span id="t1q_173" class="t s4_173">performed in order to avoid RT in patients with cT1–2 p16-negative </span>
<span id="t1r_173" class="t s4_173">oropharyngeal cancer if the primary tumors is near the midline and </span>
<span id="t1s_173" class="t s4_173">resected to adequate margins with no adverse pathologic features. </span>
<span id="t1t_173" class="t s4_173">The randomized phase II ORATOR trial aimed to compare swallow-related </span>
<span id="t1u_173" class="t s4_173">QOL outcomes in patients with early-stage T1–T2, N0–2 oropharyngeal </span>
<span id="t1v_173" class="t s4_173">cancer treated with primary RT or systemic therapy/RT, versus those </span>
<span id="t1w_173" class="t s4_173">treated with TORS with neck dissection with or without adjuvant RT or </span>
<span id="t1x_173" class="t s4_173">systemic therapy/RT. </span>
<span id="t1y_173" class="t s5_173">441 </span>
<span id="t1z_173" class="t s4_173">The study enrolled 68 patients from six hospitals </span>
<span id="t20_173" class="t s4_173">in Canada and Australia (88% p16-positive), and compared MDADI scores </span>
<span id="t21_173" class="t s4_173">between the two groups at 1 year. Swallow-related QOL outcomes </span>
<span id="t22_173" class="t s4_173">reached statistical significance favoring the primary RT cohort; however, </span>
<span id="t23_173" class="t s4_173">this difference did not meet criteria for a clinically meaningful change and </span>
<span id="t24_173" class="t s4_173">with long-term follow-up, the difference in scores became less pronounced </span>
<span id="t25_173" class="t s4_173">with the passage of time. </span>
<span id="t26_173" class="t s5_173">441,442 </span>
<span id="t27_173" class="t s4_173">Study results showed that there were </span>
<span id="t28_173" class="t s4_173">excellent and similar PFS and OS rates in both arms. The authors </span>
<span id="t29_173" class="t s4_173">concluded that “RT- and TORS-based approaches were associated with </span>
<span id="t2a_173" class="t s4_173">clinically similar QOL outcomes, but differing spectra of toxicities, and </span>
<span id="t2b_173" class="t s4_173">differences in QOL between arms decreased over time. Clinicians and </span>
<span id="t2c_173" class="t s4_173">patients should be involved in shared decision-making, in a </span>
<span id="t2d_173" class="t s4_173">multidisciplinary context, to individualize treatment of OPSCC.” </span>
<span id="t2e_173" class="t s5_173">442 </span>
<span id="t2f_173" class="t s4_173">The </span>
<span id="t2g_173" class="t s4_173">randomized open-label phase II ORATOR2 trial expanded upon the </span>
<span id="t2h_173" class="t s4_173">design of ORATOR and aimed to evaluate long-term survival, disease </span>
<span id="t2i_173" class="t s4_173">outcomes, and toxicities. </span>
<span id="t2j_173" class="t s5_173">443 </span>
<span id="t2k_173" class="t s4_173">Patients with early-stage p16-positive T1–T2, </span>
<span id="t2l_173" class="t s4_173">N0–2 oropharyngeal cancer (N = 61) were randomized to receive primary </span>
<span id="t2m_173" class="t s4_173">RT (with concurrent weekly cisplatin if node-positive disease) or TORS </span>
<span id="t2n_173" class="t s4_173">with neck dissection (with adjuvant reduced-dose RT based on pathologic </span>
<span id="t2o_173" class="t s7_173">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
